從實驗室到臨床

Day 2 10:40 - 11:15

從實驗室到臨床：加速科研成果轉化為臨床應用的進程

From Bench to Bedside: Accelerating the Lab-to-Clinic Journey

Jeremy Teoh

The Chinese University of Hong Kong,Associate Professor

張元俊醫生是香港中文大學（CUHK）醫學院外科學系副教授兼助理院長（外務）。作為泌尿腫瘤學的領先研究人員，他專門研究前列腺癌、膀胱癌和上尿路尿路上皮癌（UTUC），具有重大的學術影響（h 指數： 43）。Teoh 博士通過 SIU 2024 等會議積极參與全球泌尿外科界。

Dr. Jeremy Teoh (TEOH Yuen Chun Jeremy) is an Associate Professor in the Department of Surgery and Assistant Dean (External Affairs) at the Faculty of Medicine, The Chinese University of Hong Kong (CUHK). A leading researcher in urologic oncology, he specializes in prostate, bladder, and upper tract urothelial cancers (UTUC), with a significant scholarly impact (h-index: 43). Dr. Teoh actively engages the global urology community through conferences like SIU 2024.

Andrew Li

Won & Ha Partners,Vice President

Andrew 是一名訓練有素的神經科學家，是一位商業戰略家，致力於塑造亞洲的生命科學創新。作為Won & Ha Partners的副總裁，他説明初創公司進行籌款和市場推廣，同時為跨國公司提供併購建議。他曾擔任腫瘤液體活檢初創公司 Cellomics 的戰略總監，以及 Health Advances 的戰略顧問。他熱衷於彌合科學與商業化之間的差距。

A neuroscientist by training, Andrew is a business strategist shaping life sciences innovation across Asia. As Vice President at Won & Ha Partners, he helps startups with fundraising and go-to-market while advising multinationals on M&A. He was previously the Strategy Director at Cellomics, an oncology liquid biopsy startup, and a Strategy Consultant at Health Advances. His passion lies in bridging the gap between science and commercialization.

Daisuke Tomita

Medident Japan Oral Health Association (NPO), President

Daisuke Tomita 博士專注於數位醫療保健轉型，利用先進技術來增強醫療保健。
目前被任命為斯坦福 IT Technology 的客座講師。他獲得了哈佛大學醫療保健高管教育的領先數位醫療保健轉型學位，並擁有東京醫科齒科大學研究生院的咬合和功能正畸學博士學位。 Tomitas 博士畢業於東京昭和大學牙科學院，研究重點是整合虛擬實境、人工智慧和日本尖端技術等數字創新，以提高醫療保健的品質和可及性。

Dr. Daisuke Tomita specializes in digital healthcare transformation, leveraging advanced technologies to enhance medical care.
Currently appointed visiting instructor at Stanford IT Technology. He has earned a degree in Leading Digital Healthcare Transformation from Harvard Healthcare Executive Education and holds a D.D.S. in Occlusal and Functional Orthodontics from Tokyo Medical and Dental University’s Graduate School. A graduate of Showa University’s School of Dentistry in Tokyo, Dr. Tomita’s research focuses on integrating digital innovations such as virtual reality, artificial intelligence, and cutting-edge Japanese technology to improve the quality and accessibility of healthcare.

Adrian Lam

CorVista, CEO

Adrian 是醫療保健領域經驗豐富的投資者兼運營商，專注於醫療技術、生物技術和生命科學工具。憑藉在工程和金融市場的堅實基礎，他將科學和工程知識、基礎研究、分析洞察力和風險管理整合到企業管理、技術轉化、風險投資和投資組合管理中，通過戰略監督和實際執行來推動價值。
Adrian 擁有 8 年開發 FDA 批准的醫療器械、領導研發團隊和擴大醫療保健企業的經驗，以及在私人和公共市場的股票研究和投資組合管理方面十多年的經驗，為日益複雜、專業和當地語系化領域的風險投資開發帶來了全球性的跨學科洞察力、思想領導力和執行能力。

Adrian is an experienced investor-operator in the healthcare sector, specializing in medtech, biotech, and life science tools. With a strong foundation in engineering and financial markets, he integrates scientific and engineering knowledge, fundamental research, analytical insight, and risk management into corporate management, technology translation, venture investment, and portfolio managementdriving value through both strategic oversight and hands-on execution.
With 8 years of experience developing FDA-approved medical devices, leading R&D teams, and scaling healthcare ventures, along with over a decade in equity research and portfolio management across private and public markets, Adrian brings global, interdisciplinary insights, thought leadership, and execution capabilities to venture development in an increasingly complex, specialized, and localized field.